Published in Soc Psychiatry Psychiatr Epidemiol on July 01, 2001
The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev (2006) 6.80
Cannabis and psychosis. BMJ (2006) 2.44
Psychosocial stress and psychosis. A review of the neurobiological mechanisms and the evidence for gene-stress interaction. Schizophr Bull (2008) 1.59
Prefrontal cortical network connections: key site of vulnerability in stress and schizophrenia. Int J Dev Neurosci (2011) 1.56
Brain structure and function changes during the development of schizophrenia: the evidence from studies of subjects at increased genetic risk. Schizophr Bull (2008) 1.52
Cannabis and psychosis/schizophrenia: human studies. Eur Arch Psychiatry Clin Neurosci (2009) 1.37
Temporal association of cannabis use with symptoms in individuals at clinical high risk for psychosis. Schizophr Res (2008) 1.13
Longitudinal study of stressful life events and daily stressors among adolescents at high risk for psychotic disorders. Schizophr Bull (2009) 1.10
Chronic adolescent marijuana use as a risk factor for physical and mental health problems in young adult men. Psychol Addict Behav (2015) 1.00
The effect of cannabis on the brain: can it cause brain anomalies that lead to increased risk for schizophrenia? Curr Opin Psychiatry (2008) 0.95
Fine-tuning of awake prefrontal cortex neurons by clozapine: comparison with haloperidol and N-desmethylclozapine. Biol Psychiatry (2006) 0.94
Abnormal stress responsivity in a rodent developmental disruption model of schizophrenia. Neuropsychopharmacology (2013) 0.89
The Edinburgh High Risk Study: current status and future prospects. World Psychiatry (2003) 0.87
Interplay between childhood physical abuse and familial risk in the onset of psychotic disorders. Schizophr Bull (2014) 0.84
Visual scan paths in first-episode schizophrenia and cannabis-induced psychosis. J Psychiatry Neurosci (2007) 0.83
Cannabis and Psychosis: What Can Daily Diaries Tell Us About Who is Vulnerable? Prim psychiatry (2009) 0.76
Comorbid substance use disorders in schizophrenia: a latent class approach. Psychiatry Res (2014) 0.75
Resilience in individuals at clinical high risk for psychosis. Early Interv Psychiatry (2014) 0.75
A comparative study of socio-demographic and substance use correlates in early-onset psychosis. Early Interv Psychiatry (2016) 0.75
Psychological autopsy studies of suicide: a systematic review. Psychol Med (2003) 4.97
Childhood antecedents of schizophrenia and affective illness: social adjustment at ages 7 and 11. BMJ (1994) 3.33
Cerebral ventricular size and cognitive impairment in chronic schizophrenia. Lancet (1976) 3.14
Magnetic resonance imaging of brain in people at high risk of developing schizophrenia. Lancet (1999) 2.47
Magnetic resonance imaging studies in bipolar disorder and schizophrenia: meta-analysis. Br J Psychiatry (2009) 2.46
Structural disconnectivity in schizophrenia: a diffusion tensor magnetic resonance imaging study. Br J Psychiatry (2003) 2.31
Presenilin-I, presenilin-II, and VLDL-R associations in early onset Alzheimer's disease. Lancet (1997) 2.06
Complications of pregnancy and delivery in relation to psychosis in adult life: data from the British perinatal mortality survey sample. BMJ (1991) 2.03
Implementing evidence-based psychiatry: whose responsibility? Br J Psychiatry (2001) 1.99
Obstetric complications and age at onset in schizophrenia: an international collaborative meta-analysis of individual patient data. Am J Psychiatry (1997) 1.94
Service provision for people with schizophrenia. II. Role of the general practitioner. Br J Psychiatry (1997) 1.88
Depression after stroke and lesion location: a systematic review. Lancet (2000) 1.87
Reduced in vivo binding to the serotonin transporter in the cerebral cortex of MDMA ('ecstasy') users. Br J Psychiatry (1999) 1.86
The dementia of dementia praecox. Acta Psychiatr Scand (1978) 1.79
The Northwick Park electroconvulsive therapy trial. Lancet (1981) 1.79
Chronic fatigue syndrome: prevalence and outcome. BMJ (1994) 1.77
Working memory in schizophrenia: a meta-analysis. Psychol Med (2008) 1.76
Postmortem evidence of structural brain changes in schizophrenia. Differences in brain weight, temporal horn area, and parahippocampal gyrus compared with affective disorder. Arch Gen Psychiatry (1986) 1.74
Schizophrenic patients discharged from hospital--a follow-up study. Br J Psychiatry (1984) 1.71
Dangerous behaviour preceding first admissions for schizophrenia. Br J Psychiatry (1992) 1.71
The effects of a neuregulin 1 variant on white matter density and integrity. Mol Psychiatry (2007) 1.68
Acetylator status and response to phenelzine in depressed patients. Lancet (1973) 1.67
Neurotic illness and its response to anxiolytic and antidepressant treatment. Psychol Med (1980) 1.66
Brain structure, genetic liability, and psychotic symptoms in subjects at high risk of developing schizophrenia. Biol Psychiatry (2001) 1.59
New variant Creutzfeldt-Jakob disease: psychiatric features. Lancet (1997) 1.55
A MRI study of ocular hypertelorism in individuals at high risk of developing schizophrenia. Schizophr Res (2001) 1.54
Neuropsychological change in young people at high risk for schizophrenia: results from the first two neuropsychological assessments of the Edinburgh High Risk Study. Psychol Med (2000) 1.52
Concordance by sex in sibling pairs with schizophrenia is paternally inherited. Evidence for a pseudoautosomal locus. Br J Psychiatry (1989) 1.50
Unsuspected organic disease in chronic schizophrenia demonstrated by computed tomography. J Neurol Neurosurg Psychiatry (1980) 1.48
Mechanism of the antipsychotic effect in the treatment of acute schizophrenia. Lancet (1978) 1.47
The proportion of tumor-stroma as a strong prognosticator for stage II and III colon cancer patients: validation in the VICTOR trial. Ann Oncol (2012) 1.46
Segregation of cognitive and emotional function in the prefrontal cortex: a stereotactic meta-analysis. Neuroimage (2004) 1.44
Spontaneous involuntary disorders of movement: their prevalence, severity, and distribution in chronic schizophrenics with and without treatment with neuroleptics. Arch Gen Psychiatry (1982) 1.44
Small intestine permeability in schizophrenia. Br J Psychiatry (1989) 1.41
Chronic fatigue syndrome. Lancet (1994) 1.40
Developing training themes from HRH's delivery. Br J Psychiatry (1992) 1.38
Schizophrenia as an anomaly of development of cerebral asymmetry. A postmortem study and a proposal concerning the genetic basis of the disease. Arch Gen Psychiatry (1989) 1.38
The Northwick Park Study of first episodes of schizophrenia. I. Presentation of the illness and problems relating to admission. Br J Psychiatry (1986) 1.36
Haloperidol versus placebo for schizophrenia. Cochrane Database Syst Rev (2006) 1.35
Neuropsychological assessment of young people at high genetic risk for developing schizophrenia compared with controls: preliminary findings of the Edinburgh High Risk Study (EHRS). Psychol Med (1999) 1.34
Deficits in facial, body movement and vocal emotional processing in autism spectrum disorders. Psychol Med (2010) 1.33
Comparative trial of L-tryptophan and amitriptyline in depressive illness. Psychol Med (1976) 1.32
Obstetric complications and schizophrenia: a meta-analysis. Br J Psychiatry (1995) 1.31
A randomised controlled trial of prophylactic neuroleptic treatment. Br J Psychiatry (1986) 1.27
Genome-wide association with MRI atrophy measures as a quantitative trait locus for Alzheimer's disease. Mol Psychiatry (2010) 1.24
Volumetric magnetic resonance imaging study of the brain in subjects with sex chromosome aneuploidies. J Neurol Neurosurg Psychiatry (1999) 1.20
fMRI correlates of state and trait effects in subjects at genetically enhanced risk of schizophrenia. Brain (2004) 1.20
Hand transplantation: comparisons and observations of the first four clinical cases. Microsurgery (2000) 1.15
The relationship between acetylator status and inhibition of monoamine oxidase, excretion of free drug and antidepressant response in depressed patients on phenelzine. Psychopharmacologia (1976) 1.15
'Pfropfschizophrenie' revisited. Schizophrenia in people with mild learning disability. Br J Psychiatry (1998) 1.14
Antinuclear antibodies in psychiatric illness: their relationship to diagnosis and drug treatment. Br Med J (1975) 1.13
Diffusion tensor imaging (DTI) and proton magnetic resonance spectroscopy (1H MRS) in schizophrenic subjects and normal controls. Psychiatry Res (2001) 1.12
Comparative trial of L-tryptophan and E.C.T. in severe depressive illness. Lancet (1974) 1.11
Compliance therapy for schizophrenia. Cochrane Database Syst Rev (2006) 1.11
Edinburgh high risk study--findings after four years: demographic, attainment and psychopathological issues. Schizophr Res (2000) 1.10
Neuroanatomy of comorbid schizophrenia and learning disability: a controlled study. Lancet (1999) 1.10
Association of the mu-opioid receptor gene with smoking cessation. Pharmacogenomics J (2007) 1.09
Prevalence of psychiatric morbidity among remand prisoners in Scotland. Br J Psychiatry (1995) 1.09
Comprehensiveness of systematic review. Br J Psychiatry (1998) 1.08
Genetic variation in the dopamine D4 receptor (DRD4) gene and smoking cessation: follow-up of a randomised clinical trial of transdermal nicotine patch. Pharmacogenomics J (2007) 1.08
Invited commentaries on: Signs of asphyxia at birth and risk of schizophrenia/Obstetric complications and risk of schizophrenia. Br J Psychiatry (2001) 1.07
A diffusion tensor MRI study of white matter integrity in subjects at high genetic risk of schizophrenia. Schizophr Res (2008) 1.06
Characteristics of patients with schizophrenia or neurological disorder and virus-like agent in cerebrospinal fluid. Lancet (1979) 1.06
Schizophrenia and complications of pregnancy and labor: an individual patient data meta-analysis. Schizophr Bull (1999) 1.06
Neurodevelopmental indices and the development of psychotic symptoms in subjects at high risk of schizophrenia. Br J Psychiatry (2001) 1.05
Field efficacy and safety of an oral formulation of the novel combination anthelmintic, derquantel-abamectin, in sheep in New Zealand. N Z Vet J (2010) 1.05
Criminality and antisocial behaviour in unselected men with sex chromosome abnormalities. Psychol Med (1999) 1.04
Is the chronic fatigue syndrome best understood as a primary disturbance of the sense of effort? Psychol Med (1997) 1.03
Subcortical brain volume abnormalities in 2028 individuals with schizophrenia and 2540 healthy controls via the ENIGMA consortium. Mol Psychiatry (2015) 1.03
Set shifting and reversal learning in patients with bipolar disorder or schizophrenia. Psychol Med (2008) 1.01
Fatigue in general practice. Sex difference exaggerated. BMJ (1993) 1.01
Life events in suicide and undetermined death in south-east Scotland: a case-control study using the method of psychological autopsy. Soc Psychiatry Psychiatr Epidemiol (1999) 1.00
Lateral ventricular size in schizophrenia: relationship to the disease process and its clinical manifestations. Psychol Med (1985) 0.99
The occurrence of organic disease of possible or probable aetiological significance in a population of 268 cases of first episode schizophrenia. Psychol Med (1987) 0.99
The disabilities of chronic schizophrenia--their nature and the factors contributing to their development. Br J Psychiatry (1980) 0.99
Theory of mind and psychoses. Psychol Med (1998) 0.99
Methodological issues in volumetric magnetic resonance imaging of the brain in the Edinburgh High Risk Project. Psychiatry Res (1999) 0.98
Group psychological treatment for chest pain with normal coronary arteries. QJM (1999) 0.97
The influence of polygenic risk for bipolar disorder on neural activation assessed using fMRI. Transl Psychiatry (2012) 0.97
Childhood behaviour, psychotic symptoms and psychosis onset in young people at high risk of schizophrenia: early findings from the edinburgh high risk study. Psychol Med (2002) 0.96